Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Resources

Updates on Hematologic Malignancies: New Targeted Conditioning Regimens

: Internet Activity
: 1.0 AMA PRA Category 1 Credit(s)™
Target Audience
: Physicians, PAs
Expiration Date
: 04/25/2018

Read the content below to launch the activity


Synopsis of Program Content:
This CME-certified activity, Updates on Hematologic Malignancies: New Targeted Conditioning Regimens, will provide focused instruction to healthcare professionals caring for patients with MDS, AML, and ALL. The activity is designed to address clinical practice gaps as identified by our expert faculty and the published literature. The activity will focus on increasing clinician knowledge and the ability to integrate changes into practice to improve patient outcomes. The program will highlight current limitations in the standard of care for patients with MDS, AML, and ALL, current NCCN clinical guidelines, new research discoveries and pharmacologic agents, and current research demonstrating improved treatment outcomes for high-risk patients with relapsed disease or difficult-to-treat cytogenetics. Topics for presentation and discussion will include: proper selection of dose-intensity for chemotherapeutic options in MDS and AML, conditioning regimens for ALL prior to HSCT, and improvements in clinical outcomes for new and emerging targeted-conditioning regimens.

Learning Objectives
After completing this CME activity, the participant will be able to:

1. Define the cytogenetic and biological disease characteristics of hematologic malignancies (MDS, AML, ALL) that inform the appropriate selection of available treatment options and HSCT for high-risk patients

2. Explain the NCCN and other expert guidelines for the management of MDS, ALL, and AML in high-risk patients with advanced age,  comorbidities, relapsed disease, and particular genetic mutations

3. Identify the currently recommended conditioning regimens, toxicities, support strategies and associated outcomes for patients with  hematologic malignancies (MDS, AML, ALL)

4. Discuss the safety and efficacy data of emerging conditioning agents for hematologic malignancies, including refractory/relapsed MDS, AML, and ALL, and their potential for enhanced clinical outcomes


Sergio A. Giralt, MD
Program Chair
Professor of Medicine
Weill Cornell College of Medicine
Chief Attending, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY

David I. Marks, MBBS, PhD
Professor of Haematology and Stem Cell Transplantation
University of Bristol
Bristol BMT Unit
University Hospitals Bristol NHS Trust
Bristol, UK

Bart L. Scott, MD
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine, Division of Oncology
University of Washington
Director of Hematology and Hematologic Malignancies
Seattle Cancer Care Alliance
Seattle, WA